With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Chemotherapy before surgery helps patients with nose and sinus cancer avoid debilitating eye and bone removal

2.

Classifying childhood brain cancers by immune response may improve diagnostics and treatments

3.

No Solace From Drug Scarcities; Novel Guidelines Regarding Lymphedema; A "Good" Patient Is Forgotten.

4.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

5.

Adult overdose deaths on the rise


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot